<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00388882</url>
  </required_header>
  <id_info>
    <org_study_id>205.346</org_study_id>
    <secondary_id>EudraCT 2006-000822-30</secondary_id>
    <nct_id>NCT00388882</nct_id>
  </id_info>
  <brief_title>Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with
      tiotro pium HandiHaler® 18 mcg daily compared to Combivent® MDI CFC Inhalation Aerosol 2
      actuations qid in COPD patients currently prescribed Combivent® MDI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Trough FEV1</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1 AUC0-6 hours</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1</measure>
    <time_frame>after first dose and 6 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-6 hours</measure>
    <time_frame>after first dose and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1</measure>
    <time_frame>at 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC at all clinic visits</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-6 hours FVC at all clinic visits</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC</measure>
    <time_frame>at 6 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual FEV1 measurements</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual FVC measurements</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Albuterol (scheduled and rescue)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Evaluation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Evaluation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEFR (Peak expiratory flow rate) measured by the patient at home twice daily</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">327</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ipratropium bromide / albuterol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COPD

          -  Age: &gt;= 40 years

          -  Current or ex-smoker with a &gt;= 10 pack-year smoking history

          -  Use of Combivent® MDI for &gt;= 1 month prior to Visit 1 Spirometric criteria (determined
             at study visits):

          -  Post-bronchodilator FEV1 &lt;= 70% (Visit 1)

          -  Pre-bronchodilator FEV1 &lt;= 65% of predicted and FEV1/FVC &lt;= 70% (Visit 2)

        Exclusion Criteria:

          -  Clinical history of asthma

          -  History of thoracotomy with pulmonary resection

          -  History of CF, alpha 1 antitrypsin deficiency or interstitial lung disease

          -  Daytime use of oxygen therapy for &gt; 1 hour per day or if unable to abstain from using
             oxygen during PFTs

          -  Any respiratory tract infection or COPD exacerbation in 6 weeks prior to Visit 1

          -  Recent history 6 months or less of MI

          -  Unstable or life-threatening cardiac arrhythmias

          -  Hospitalization for CHF during past year

          -  Malignancy for which patient is receiving chemo or radiation therapy

          -  Pregnant or nursing women

          -  Known hypersensitivity to ipratropium or carrier substances, including related food
             products such as soybean, peanuts, or lactose

          -  Use of SPIRIVA® 3 months prior to Visit 1

          -  Symptomatic of prostatic hypertrophy or bladder neck obstruction

          -  Known narrow- angle glaucoma

          -  Participating in a pulmonary rehab program within 4 weeks of Visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.346.107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sepulveda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.510</name>
      <address>
        <city>Bs As</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.508</name>
      <address>
        <city>Buenos Airess</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.502</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.503</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.505</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.509</name>
      <address>
        <city>Rosario, Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.511</name>
      <address>
        <city>Rosario, Santa Fé</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.504 Instituto de Patologías Respiratorias</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alytus</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.411 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Siauliai</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Utena</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Levica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.306 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sturovo</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aylesbury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenisland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Soham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.209 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westbury On Trym</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.346.205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Windsor</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Lithuania</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/19737620</url>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2006</study_first_submitted>
  <study_first_submitted_qc>October 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2006</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

